Baseline of N-terminal proBNP levels and efficacy parameters of nine patients in CUPID 1 trial
| Cohort/patient identification | Baseline of N-terminal proBNP (pg/mL) | Efficacy parameters (study time) |
| Cohort 1/patient 1 | 315 | Improve (12 months) |
| Cohort 1/patient 2 | 2329 | Worsen (receive a transplant at month 8) |
| Cohort 1/patient 3 | 2928 | Improve (12 months) |
| Cohort 2/patient 1 | 1420 | Improve (died of presumed sudden cardiac death at 96 days) |
| Cohort 2/patient 2 | 5236 | Improve (12 months) |
| Cohort 2/patient 3 | 2596 | Improve (12 months) |
| Cohort 3/patient 1 | 770 | Improve (6 months) |
| Cohort 3/patient 2 | 458 | Improve (6 months) |
| Cohort 3/patient 3 | 30 704 | Worsen (receive a mechanical support device at week 6) |
CUPID, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease; N-terminal proBNP, N-terminal pro-B-type natriuretic peptide.